RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..1 of 1 - per page
Order by
Use of Biological Surfactant as Anti-flammatory Agent and Tissue Preservative Solution
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
Displaying 1..1 of 1 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Sepsis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Jul 2011 - 84 pages - $2,000
Sepsis - Pipeline Review, Q2 2011
Apr 2011 - 104 pages - $500
Sepsis - Pipeline Review, H2 2011
Aug 2011 - 157 pages - $500
Epidemiology: Sepsis – The incidence of severe sepsis is on the rise due to the dramatic aging populations across the developed world
Mar 2011 - 33 pages - $5,700
Sepsis - Pipeline Review, Q4 2010
Dec 2010 - 63 pages - $500
Case Study: Sepsis - Xigris’ disappointing performance creates a market opportunity for improved sepsis therapies
May 2011 - 36 pages - $1,900
Sepsis Therapy Area Pipeline Report
Nov 2010 - 85 pages - $1,495
National Heart, Lung, and Blood Institute – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
Mar 2008 - 250 pages - $3,995
Celldex Therapeutics, Inc. - SWOT Analysis
Nov 2010 - 20 pages - $125
More Related Market Research Reports >>>

Your selection

Industry sector
Biotechnology del
Human therapeutics del
Therapeutic target
Blood and forming organs del
Sepsis del

Browse By

Development phase
Early Stage
Preclinical
Phase I
Phase I/II
Phase II
Phase III
Phase III/IV
Preregistration
Registered

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us